Osteopetrosis: genetics, treatment and new insights into osteoclast function

Cristina Sobacchi, Ansgar Schulz, Fraser P. Coxon, Anna Villa, Miep H. Helfrich

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Osteopetrosis is a genetic condition of increased bone mass, which is caused by defects in osteoclast formation and function. Both autosomal recessive and autosomal dominant forms exist, but this Review focuses on autosomal recessive osteopetrosis (ARO), also known as malignant infantile osteopetrosis. The genetic basis of this disease is now largely uncovered: mutations in TCIRG1, CLCN7, OSTM1, SNX10 and PLEKHM1 lead to osteoclast-rich ARO (in which osteoclasts are abundant but have severely impaired resorptive function), whereas mutations in TNFSF11 and TNFRSF11A lead to osteoclast-poor ARO. In osteoclast-rich ARO, impaired endosomal and lysosomal vesicle trafficking results in defective osteoclast ruffled-border formation and, hence, the inability to resorb bone and mineralized cartilage. ARO presents soon after birth and can be fatal if left untreated. However, the disease is heterogeneous in clinical presentation and often misdiagnosed. This article describes the genetics of ARO and discusses the diagnostic role of next-generation sequencing methods. The management of affected patients, including guidelines for the indication of haematopoietic stem cell transplantation (which can provide a cure for many types of ARO), are outlined. Finally, novel treatments, including preclinical data on in utero stem cell treatment, RANKL replacement therapy and denosumab therapy for hypercalcaemia are also discussed.

Original languageEnglish
Pages (from-to)522-536
Number of pages15
JournalNature Reviews Endocrinology
Volume9
Early online date23 Jul 2013
DOIs
Publication statusPublished - Sep 2013

    Fingerprint

Keywords

  • Animals
  • Humans
  • Osteopetrosis
  • RANK Ligand
  • Signal Transduction

Cite this